Independent Meta-Analysis Shows SkylineDx's Merlin CP-GEP Assay Accurately Stratifies Patients for Sentinel Lymph Node Biopsy Selection

SkylineDx United States of America Netherlands United Kingdom California

The independent meta-analysis assessed the overall predictive performance of the CP-GEP model, which demonstrated a high Sensitivity Rate (93%) and Negative Predictive Value (95%) across all stages, reinforcing its reliability and effectiveness as a clinical tool to guide decisions around SLNB.CP-GEP model is an effective deselection tool for SLNB, allowing clinicians to identify patients who can forgo the invasive surgical procedure and its potentials complications.Despite diversity among the studies, CP-GEP performed consistently in identifying those at low risk of sentinel lymph node metastasis.and www.merlinmelanomatest.com

About SkylineDx

SkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, inflammatory and infectious diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient's response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in Rotterdam, the Netherlands, complemented by a US base of operations and a CAP/CLIA certified laboratory in San Diego California, USA. To learn more about SkylineDx, please visit www.skylinedx.com.

Footnotes:

Predictive Performance of the Clinicopathologic Gene Expression Profile (CP-GEP) in Identifying Cutaneous Melanoma Patients for Whom Sentinel Lymph Node Biopsy is Unnecessary: A Systematic Review and Meta-Analysis. Terence Wong, Sydney Ch'ng, Peter Ferguson , Linda Martin , Alexander M Menzies , Inês Pires da Silva, Georgina V Long , Richard A Scolyer, Alexander van Akkooi, Serigne N Lo.  Link to the publication.

Media Contact:

ICR Healthcare
Alexis Feinberg
[phone]
[e-mail] 

 

View original content:https://www.prnewswire.co.uk/news-releases/independent-meta-analysis-shows-skylinedxs-merlin-cp-gep-assay-accurately-stratifies-patients-for-sentinel-lymph-node-biopsy-selection-302498198.html